Dr. Vibha Jawa is Chief Scientific Officer at EpiVax, where she leads scientific strategy and innovation in immunogenicity and translational science. Previously, she held leadership roles at Bristol Myers Squibb, Merck, and Amgen, supporting biologics, vaccines, and cell and gene therapy development. With more than 20 years of industry experience, she has contributed to more than 20 IND, BLA, and MAA filings. Jawa has authored more than 75 peer-reviewed publications and serves in multiple leadership roles within AAPS and other scientific organizations. She was named an AAPS Fellow in 2022.
Advances in predictive modeling, translational bioanalytics, and human-relevant research systems may help reduce reliance on animal testing while improving the clinical relevance of preclinical drug development. Experts say these approaches could streamline IND preparation, lower costs, and support more informed decision-making across biopharmaceutical R&D.
Vibha Jawa, PhD, discussed evolving approaches to preclinical development, animal use reduction, and immunogenicity assessment during an interview with BioPharm International at AAPS NBC 2026.
